GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Flora Growth Corp (NAS:FLGC) » Definitions » Net-Net Working Capital

Flora Growth (Flora Growth) Net-Net Working Capital : $-1.19 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Flora Growth Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Flora Growth's Net-Net Working Capital for the quarter that ended in Mar. 2024 was $-1.19.

The industry rank for Flora Growth's Net-Net Working Capital or its related term are showing as below:

FLGC's Price-to-Net-Net-Working-Capital is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.53
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

Flora Growth Net-Net Working Capital Historical Data

The historical data trend for Flora Growth's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Flora Growth Net-Net Working Capital Chart

Flora Growth Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Net-Net Working Capital
- 6.14 10.68 -1.28 -0.80

Flora Growth Quarterly Data
Jun19 Dec19 Jun20 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.38 -1.68 -0.70 -0.80 -1.19

Competitive Comparison of Flora Growth's Net-Net Working Capital

For the Drug Manufacturers - Specialty & Generic subindustry, Flora Growth's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Flora Growth's Price-to-Net-Net-Working-Capital Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Flora Growth's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Flora Growth's Price-to-Net-Net-Working-Capital falls into.



Flora Growth Net-Net Working Capital Calculation

Flora Growth's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net-Net Working Capital(A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(4.35+0.75 * 1.984+0.5 * 8.508-17.222
-0-0)/8.935
=-0.80

Flora Growth's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2024 is calculated as

Net-Net Working Capital(Q: Mar. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(4.156+0.75 * 2.278+0.5 * 9.246-21.136
-0-0)/8.981
=-1.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Flora Growth  (NAS:FLGC) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Flora Growth Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Flora Growth's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Flora Growth (Flora Growth) Business Description

Traded in Other Exchanges
N/A
Address
3406 South West 26th Terrace, Suite C-1, Fort Lauderdale, FL, USA, 33132
Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are; the commercial and wholesale segment (FGH and Cosechemos subsidiaries), the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries), and the pharmaceuticals segment (Grupo Farmaceutico Cronomed and Breeze Laboratory subsidiaries). Geographically, the company operates in the United States, Germany, Colombia, the United Kingdom, and Canada. it derives a majority of its revenue from the United States.
Executives
Thomas Solomon director C/O FLORA GROWTH CORP., 365 BAY STREET; SUITE 800, TORONTO Z4 M5H 2V1
Kevin Taylor director C/O COOL HOLDINGS, INC., 2001 NW 84TH AVENUE, MIAMI FL 33122
Hussein Rakine director, officer: Chief Executive Officer 5258 SW 183RD AVENUE, MIRAMAR FL 33029
Clifford Starke director, officer: President C/O FLORA GROWTH CORP., 3405 SW 26TH TERRACE, SUITE C-1, FORT LAUDERDALE FL 33312
Edward Woo director C/O FLORA GROWTH CORP., 3405 SW 26TH TERRACE, SUITE C-1, FORT LAUDERDALE FL 33312
John Timothy Leslie director C/O FLORA GROWTH CORP., 3405 SW 26TH TERRACE, SUITE C-1, FORT LAUDERDALE FL 33312
Marc Mastronardi director C/O FLORA GROWTH CORP., 3405 SW 26TH TERRACE, SUITE C-1, FORT LAUDERDALE FL 33312
Jason Warnock officer: CCO C/O FLORA GROWTH CORP., 3405 SW 26TH TERRACE, SUITE C-1, FORT LAUDERDALE FL 33312
Annabella Manalo Morgan director C/O FLORA GROWTH CORP., 3405 SW 26TH TERRACE, SUITE C-1, FORT LAUDERDALE FL 33312
Jessie Casner officer: CMO C/O FLORA GROWTH CORP., 3405 SW 26TH TERRACE, SUITE C-1, FORT LAUDERDALE FL 33312
Dany Vaiman officer: Sr. VP Finance C/O FLORA GROWTH CORP., 3405 SW 26TH TERRACE, SUITE C-1, FORT LAUDERDALE FL 33312
Elshad Garayev officer: CFO C/O FLORA GROWTH CORP., 3405 SW 26TH TERRACE, SUITE C-1, FORT LAUDERDALE FL 33312
Beverley Richardson director C/O FLORA GROWTH CORP., 3405 SW 26TH TERRACE, SUITE C-1, FORT LAUDERDALE FL 33312
Roa Juan Carlos Gomez director C/O FLORA GROWTH CORP., 3405 SW 26TH TERRACE, SUITE C-1, FORT LAUDERDALE FL 33312
Luis Merchan director, officer: CEO & Chairman of the Board C/O FLORA GROWTH CORP., 3405 SW 26TH TERRACE, SUITE C-1, FORT LAUDERDALE FL 33312